



Healios to participate in a webcast on innovating for ophthalmic diseases

Tokyo, Japan— October 13, 2016 — Hardy TS Kagimoto, MD, President, Representative Director and CEO of HEALIOS K.K. will participate in a BioPharma Dealmakers webcast, sponsored in part by Healios, featuring three companies innovating in therapies for eye disorders. The webcast, part of the BioPharma Dealmakers series, is scheduled for 10:00 am ET on October 20th.

[> Webcast registration link](#)

This webcast will explore some of the latest advances in the ophthalmic field through discussion with representatives from companies developing a range of innovative therapies for eye disorders, including the use of iPS cells, eye drops to deliver small-molecule drugs and complement inhibition.

The webcast will conclude with a live roundtable discussion and a Q&A section to allow you to participate and put your own questions to the speakers.

Hardy TS Kagimoto founded Healios K.K. in 2011 to realize his driving objective, the development of a therapy for age-related macular degeneration. Other webcast participants include:

- **Cedric Francois, MD, PhD**, Co-founder & CEO/President of Apellis
- **Dr. George Nikopoulos**, CEO & President of Mannin Research Inc.
- **Moderator: Raveena Bhambra**, Editor of *BioPharma Dealmakers*. Raveena has worked in the biopharma industry for over 10 years specifically in the areas of dealmaking, partnering and licensing.

About the Webcast

[BioPharma Dealmakers webcasts](#) are dedicated to small and large companies looking for commercial partnerships. Read the quarterly [BioPharma Dealmakers supplement](#) in *Nature Biotechnology* and *Nature Reviews Drug Discovery*.

About HEALIOS K.K.

Healios is a biotechnology venture leading the field of developing iPS cell-based products for regenerative medicine. It was founded in 2011 and listed on the stock exchange (Tokyo Security Exchange Mothers: 4593) in 2015. In Japan, the company is developing a product for treatment of age-related macular degeneration (an intractable

ocular disease) jointly with Sumitomo Dainippon Pharma Co., Ltd. In fields other than ophthalmology, the company has started R&D of products for regenerative medicine capable of creating functional human organs (three-dimensional organs) jointly with Yokohama City University. The company may be viewed as an enterprise providing products for regenerative medicine as a solution to the significant global issue “aging of the society.” More information is available at <https://www.healios.co.jp/en/>.

Contact:
HEALIOS K.K.
Corporate Communication Group
pr@healios.jp